Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel.

Megan MelodySangeetha GandhiZaid Abdel RahmanPaula Lengerke-DiazNicole GannonAllison RosenthalTuan TruongMattia NovoEva BrandesGina LangeBreana EstbyPatrick JohnstonSteve AnsellN Nora BennaniJonas PaludoJose Villasboas BisnetoErnesto AyalaHan W TunHemant S MurthyVivek RoyJames ForanJanuario CastroYi LinMohamed A Kharfan-Dabaja

Published in: European journal of haematology (2021)

Notwithstanding the limitations related to the relatively small sample size, axi-cel therapy appears to overcome the adverse effect of hypoalbuminemia on OS and PFS. Large multicenter clinical studies are certainly needed to validate these findings.

Keyphrases

diffuse large b cell lymphoma
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
hodgkin lymphoma
cross sectional
stem cells
emergency department
double blind
mesenchymal stem cells
adverse drug